Initially, we revealed that DCA-treated ApoE−/− mice fed with a WD displayed a dramatic decrease in body weight and improved dyslipidemia; this effect was similar to the anti-hyperglycemic effect of metformin, which reduces the VLDL–TG level that results from enhanced VLDL–TG uptake and intracellular TG lipolysis followed by mitochondrial fatty acid oxidation in BAT in a manner that is independent of hepatic VLDL–TG production37. The gene discussed is APOE; the disease is metabolic syndrome.